Surveillance
Individuals with KCNA2-related disorder are regularly seen by a neurologist to monitor antiepileptic drug levels, to perform EEG recordings, motor and cognitive development. Motor and cognitive development is assessed with neuropsychological evaluations when appropriate.
Treatment of manifestations
Anti-seizure medication is used to minimize seizure frequency. Rehabilitation of motor and cognitive functions is recommended. Physical therapy is recommended to maximize mobility as well as the use of durable medical equipment as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).
Precision medicine approaches
Several pathogenic variants have been confirmed to result in either gain or loss of function of the Kv1.2 potassium channel. Particularly gain-of-function variants have been investigated and treated with the channel-specific blocker 4-aminopyridine. This precision medicine approach resulted in a marked improvement of the symptoms in a limited number of affected individuals, comprising reduction of seizure frequency (repeatedly resulting in seizure freedom), improved gait, ataxia, alertness, cognition, or speech.
However, double-blinded placebo-controlled clinical trials have not yet been performed in KCNA2-related disorder.
KCNA2